Welcome to our dedicated page for Moolec Science news (Ticker: MLEC), a resource for investors and traders seeking the latest updates and insights on Moolec Science stock.
Moolec Science SA reports developments tied to its molecular farming and precision fermentation platform for food ingredients, including engineered plants and microbes designed to produce scalable protein solutions. News commonly covers the GLASO1 safflower platform for gamma-linolenic acid oils, animal-protein expression in crops such as pea seeds, and pipeline categories that include alternative proteins, bioactive compounds, nutritional oils and biological inputs.
Company updates also include public-company matters such as Nasdaq listing compliance, share consolidation, capital structure actions, and accounting effects from subsidiary derecognition. The recurring themes combine technology commercialization, agricultural and processing performance, intellectual property, and governance or listing-status developments.
Moolec Science (NASDAQ:MLEC) announced a 15-for-1 share consolidation of its ordinary shares, effective at 8:00 a.m. ET on January 5, 2026. The consolidation will change par value from US$0.10 to US$1.50 per share and reduce issued and outstanding shares from 10,891,761 to approximately 726,118. Fractional shares will be rounded up to whole shares; no fractional share certificates will be issued. The consolidated shares will begin trading on Nasdaq Capital Market under CUSIP G6223S125 upon market open on January 5, 2026. The company says the Share Consolidation is intended to regain compliance with Nasdaq's minimum bid price rule (Rule 5550(a)(2)).
Moolec Science (NASDAQ:MLEC) announced completion of its 2025 U.S. GLASO1 safflower campaign, marking its first large-scale deployment of a plant-engineered molecular farming platform.
Key outcomes: 1,100 acres cultivated, average yield ~2,200 lb/acre versus 1,400 lb/acre in 2024 (a 57.1% YoY increase), and acreage expanded by more than 100% versus prior cycles. The company says harvests exceeded internal forecasts and validated large-volume harvest management, traceability, and quality controls.
Moolec plans to enter the U.S. nutrition and supplements market and pursue high-concentration GLA softgel applications to access premium channels and recurring demand.
Moolec Science (NASDAQ:MLEC) received a Nasdaq determination letter dated November 24, 2025, stating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) for failing to file its Annual Report on Form 20-F for year ended June 30, 2025 with the SEC.
The company attributed the delay to post-closing complexities from a mid-June 2025 business combination that triggered reverse acquisition accounting and valuation work. Moolec filed a Form 12b-25 on October 31, 2025, and requested a stay of suspension; the stay remains in effect pending a Nasdaq Hearings Panel hearing scheduled for December 18, 2025. Ordinary shares will continue trading on The Nasdaq Capital Market under the symbol MLEC during the stay. The company expects to file the Form 20-F before the hearing.
Moolec Science (NASDAQ:MLEC) received a Nasdaq determination letter dated November 14, 2025, notifying the company that its closing bid price had been below the $1.00 minimum for the last 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2).
The letter indicated Nasdaq's view that the company would not receive an automatic 180-day compliance period. Moolec submitted a timely appeal to a Nasdaq Hearings Panel and requested a 180-day period to file and implement a compliance plan, which may include a reverse stock split if in shareholders' best interest.
The appeal automatically stays the determination until the hearing on December 18, 2025, and the company's ordinary shares will continue to trade as MLEC during the stay. The company said the letter does not affect its business operations or SEC reporting obligations.
Moolec Science (NASDAQ:MLEC), a biotechnology company focused on engineering plants and microbes for protein solutions, announced three significant developments. First, the company received regulatory approval from SENASA in Argentina for its safflower GLASO technology, enabling expansion of its GLA-enriched safflower crop production. Second, Moolec has doubled its U.S. safflower acreage compared to last year, strengthening its supply capabilities for the pet food and human nutrition markets.
Additionally, the company appointed Valeria Falottico as CFO, bringing over 20 years of financial expertise. Moolec also completed the integration of Mycofood™, its fungal-based protein platform, which is currently developing products for evaluation by food industry partners in North America and Europe.
Moolec Science (NASDAQ:MLEC) has announced a transformational all-stock Business Combination Agreement with Bioceres Group and other entities. The deal involves Moolec issuing up to 87 million new shares and 5 million warrants to acquire Bioceres Group, Nutrecon , and Gentle Technologies Corp.
The combined entity will control a portfolio of over 800 patents and 550 product registrations, representing more than half a billion dollars in annual sales across 50+ countries. The transaction positions Moolec as a comprehensive agricultural technology company, integrating molecular farming, biological inputs, and climate-resilient seeds.
Key highlights include:
- Continued development of molecular farming products (Piggy Sooy™, GLASO™)
- Integration of biological agricultural solutions through Bioceres Group
- Expansion into R&D and CDMO services under Agrality® and Synbio Powerlabs®
- Development of emerging technologies in biomaterials and farm equipment
Moolec Science SA (NASDAQ:MLEC) has received a Nasdaq Staff Determination Letter on March 11, 2025, indicating non-compliance with listing requirements as its stock price remained below $1.00 for over 30 consecutive business days since September 10, 2024. The company is not eligible for a second 180-day compliance period due to not meeting the $5,000,000 minimum stockholders' equity requirement.
On March 13, 2025, Moolec appealed the determination and plans to present a compliance strategy involving a reverse share split. The appeal temporarily halts any delisting actions. The Board of Directors has resolved to convene an extraordinary shareholders meeting to vote on the reverse share split. Without securing an extension from the Hearings Panel or achieving compliance, the company's ordinary shares and warrants face potential delisting from Nasdaq.